Comparing Thailand and UK's Reimbursement Policies: Focus on High-Value Drug List for Cancer

Abstract

This review’s objective to analyze Thailand's drug reimbursement and patient access in comparison to the United Kingdom's (UK) universal health coverage system, with a focus on evidence-based reimbursement for fiscal stability. Materials and Methods, a comparative analysis was conducted, utilizing a random search of the latest regulations and several sources, employing the most relevant keywords of reimbursement policy, high-value drug, national list of medicine, Thailand, and United Kingdom. Thematic alignment and differentiation between Thailand and the UK were explored. Finding, Thailand's healthcare system relied on three insurance schemes, with rising per capita health spending and evolving trends compared to the UK. The National Essential Drug List (ED) and Hospital Drug List (HDL) ensured equitable medication access, alongside the Health Technology Assessment (HTA) and drug reimbursement policy. The inclusion of targeted and biological drugs in the High-Value Drug List for the Oncology and Hematology Program was highlighted. Government reference pricing mechanisms were explored, revealing differences impacting patient access. Suggestion, Thailand's comprehensive drug reimbursement framework, including the OCPA program, exemplified efforts to manage costs effectively and expand access to high-value drugs. In contrast, the UK maintained universal coverage under the NHS, with mechanisms like the PPRS and IFR ensuring reasonable pricing and equitable access. However, variations existed in patient access to high-value drugs, influenced by medical conditions and healthcare scheme affiliation. Streamlining pre-authorization processes and enhancing collaboration with pharmaceutical companies were recommended to improve access and affordability.